Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 12/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544837 | 1.00 | PTPRB (0.46) | PTPRBSLC40A1ATMHDAC1HDAC6 | |
| SCHEMBL13285667 | 0.91 | PTPRB (0.37) | PTPRBSLC40A1ATMHDAC1HDAC6 | |
| SCHEMBL1744294 | 0.90 | HDAC1 (0.36) | PTPRBSLC40A1HDAC1HDAC6CYP3A4 | |
| SCHEMBL12241784 | 0.89 | PTPRB (0.47) | PTPRBATMHDAC1HDAC6CYP3A4 | |
| SCHEMBL1743725 | 0.87 | TSHR (0.35) | PTPRBSLC40A1HDAC1HDAC6CYP3A4 | |
| SCHEMBL12267269 | 0.80 | ATM (0.37) | PTPRBATMCYP3A4 | |
| SCHEMBL12241786 | 0.79 | PTPRB (0.39) | PTPRBATMCYP3A4 | |
| SCHEMBL12241789 | 0.79 | PTPRB (0.49) | PTPRBATMHDAC1HDAC6 | |
| SCHEMBL12277487 | 0.79 | PTPRB (0.34) | PTPRBATMHDAC1HDAC6CYP3A4 | |
| SCHEMBL1742045 | 0.78 | HDAC1 (0.38) | SLC40A1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | PTPRB 879/4885SLC40A1 3070/4885ATM 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.